Introduction
In recent years, there has been great interest in the role that precision medicine might play in the treatment of patients with pancreatic ductal adenocarcinoma (PDA) who have an overall five year survival rate of nine percent [1] . After decades of research investigating this devastating disease, the main treatment options for advanced disease are a combination of chemotherapeutics [2, 3] that offer only a limited survival benefit [4, 5] . For example, ESPAC-4 showed a survival benefit of just over two months in patients with resected PDA receiving gemcitabine and capecitabine over gemcitabine alone [3] . The minimal survival benefit and known cytotoxicity of these available regimens make it imperative to explore novel therapeutic options for these patients. Thus, it is important to develop methods that can accurately select patients who may derive benefit from existing targeted therapies (i.e., a personalized therapeutic approach). One method to streamline this process is to consent a patient for molecular profiling at the time of surgical consent, and at the time of resection, send it directly for sequencing. Once processed and analyzed these results can be made available seamlessly into an electronic health record system for the provider [6] .
The main goal of molecular profiling is to understand the specific biologic events driving a patient's tumor. In the process of profiling, the hope is to identify actionable mutations that can be targeted with therapy [7] . The foundation of molecular profiling is next generation sequencing (NGS) which can identify mutations, gene copy number alterations, and rearrangements [8] [9] [10] , and has been applied in several studies of PDA [11] [12] [13] [14] . The multitude of potentially actionable mutations identified in PDA parallels other tumor types [7, [15] [16] [17] . In fact, it was estimated in a recent study that roughly a quarter of all PDAs sequenced have an actionable mutation [6] . Personalized oncology has been applied to recent "basket studies" that categorize patients based on their actionable mutation for therapy as opposed to their pathology or tumor type [18] [19] [20] [21] [22] .
Based on the aforementioned studies, we aimed to test the feasibility of consenting and profiling patients with PDA from a high volume single institution practice [23] . We focused primarily on resected PDA patients, with the ultimate goal to develop a personalized therapeutic approach that would complement surgical resection of this disease.
Methods

Patients
For this study, our inclusion criteria included any patient from Thomas Jefferson University (TJU) with hepatopancreaticobiliary cancers who agreed and gave consent for this study from December 2014 to September 2017. All patients had a tissue diagnosis of pancreatic ductal adenocarcinoma (PDA) cancer, either endoscopic or surgical, but did not have to be a surgical candidate necessarily. For the purposes of this study, all other non-PDA samples were excluded for this study analysis. Patients were enrolled during December 2014 to September 2017 and offered participation in the study. This study was performed with IRBapproval and an approved biobanking protocol.
Multi-omic profiling and therapy recommendation
To assess patient tumors for potentially actionable findings, resection or biopsy specimens were sent to Perthera, Inc. (McLean, VA) for a comprehensive multi-omic profile. Perthera, in collaboration with TJU, collected clinicopathologic data, including tumor characteristics and past treatment history for correlational analysis. Clinical variables included gender, age, smoking history, past medical history (diabetes, pancreatitis, hypertension, hyperlipidemia, arthritis, GERD, obesity), and family history of cancer. Pathologic variables assessed included stage at diagnosis, location of tumor (head vs. body/tail), tumor grade, tumor size, pathologic staging, lymph node positivity, presence of IPMN, lympho-vascular invasion, and perineural invasion. To see if there were any association between pathological variables and molecular variables, we performed statistical analysis on NGS samples with a cutoff of three or more genes mutated, or IHC samples with a cutoff of four or more gene alterations. This yielded 39 variables, for a total of 741 comparisons.
Tissue specimens collected were sent to CLIA-certified, CAPaccredited labs for two types of profiling: next generation sequencing (NGS) using the FoundationOne test from Foundation Medicine, Inc. (Cambridge, MA) and protein immunohistochemistry (IHC) from either Caris Life Sciences (Irving, TX) or NeoGenomics (Fort Myers, FL). The FoundationOne testing platform was used to compare patient sample genomics to 315 cancer-related genes plus introns from 28 genes often altered in cancer to identify these cancer driver genes [24] . The clinical and molecular data were integrated and processed in the Perthera Therapeutic Intelligence Engine to generate matching therapies and clinical trials.
Data infrastructure processing
To assure a streamline process, samples once collected were sent directly to Perthera and their collaborating companies for NGS processing and FoundationOne testing. Once the reports were generated, Perthera's molecular tumor board reviewed the treatment recommendations individually and provided a summary to the referring physician. The referring physician would then review the findings and conclusions with the patients to discuss their therapy options. Further details on the Perthera workflow and method development have been previously published [6] .
Statistical analysis
Correlations among molecular and clinicopathologic variables were assessed using Fisher's exact test, implemented with the fisher.test function in the stats package of the R statistical programming language. Correlations between molecular and clinicopathologic variables and recurrence-free survival (RFS) and overall survival (OS) were assessed using a log-rank test of Kaplan-Meier survival estimates, implemented using the survdiff function in the survival package of R.
Results
All samples: tissue collection rates for all patients included
During the study timeframe, Perthera delivered multi-omic profiling reports for a total of 78 TJU patients with hepatopancreaticobiliary cancers. The majority of these were pancreatic ductal adenocarcinoma cases (PDA, n ¼ 65, Table 1 ), and the remaining 13 cases were non-PDA cancers and were excluded from this study analysis. Although tissue specimen quality is often a limiting factor in obtaining molecular test results, genomic and proteomic profiling had high success rates in this study. NGS results were obtained for all the patients, while IHC results were obtained for nearly all the patients (75/78, 96%). For the current analysis, we focused only on PDA samples collected for molecular testing (n ¼ 65) for this study's analysis.
Multi-omic profiles reveal therapeutic actionability in half of the patients with PDA
Actionable alterations are defined as mutations in the person's genome that can be specifically targeted by molecular therapies against that mutation. In the 65 PDA cases, pathogenic mutations were detected in all tumor specimens, with a median of 3.5 pathogenic mutations or copy number alterations (CNA) per patient. Common PDA driver mutations were present at the expected frequencies ( Fig. 1 ) [12] : KRAS mutations [25] were seen in 62/65 (95%) cases, TP53 mutations [25] found in 49/65 (75%), CDKN2A mutations or losses [25] found in 25/65 (38%), and SMAD4 mutations or losses [25] found in 16/65 (25%). Additionally, out of the 65 patients with PDA, 47% of patients had mutations in targetable genes, such as genes important for homologous recombination [26] (11/16, 17%), or AKT/PIK3CA amplification [27] and ARID1A/STK11 mutations [27] involving the PI3K/mTOR pathway (8/65, 12%)-these are actionable mutations that can be targeted with therapies that exploit these mutations and pathways. As published in large sequencing studies [28, 29] , the most common actionable alterations in PDA patients were mutations in the DNA damage response pathway 8-10% [6, 30, 31] which can be targeted by platinum agents and PARP (poly ADP ribose polymerase) inhibitors. Other less common actionable abnormalities (and the potential associated therapies) included FGFR alterations (FGFR inhibitors; 5/65, 8%); HER2 amplifications [32] and/or ERRB2 activating mutations (HER2 inhibitors, 3/65, 5%), and RNF43/GNAS/FAT1 mutations important for the WNT pathway [33, 34] that can be targeted with WNT inhibitors (3/65, 5%, Fig. 1 ).
Correlations among molecular and clinical variables
Molecular and clinicopathologic data were systematically analyzed for correlations in the 52/65 surgically resected PDA specimens. Clinical variables included gender, age, smoking history, other medical conditions and family history of cancer. Testing for associations using Fisher's exact test revealed that 36 of these comparisons were significant at a threshold of p < 0.05 ( Table 2) .
Multiple significant correlations (p < 0.05) between common PDA driver genes were observed. CDKN2A mutations or copy number losses were more frequent when TP53 was mutated (p ¼ 0.031). SMAD4 mutations were more common in tumors with mutations at the p14 ARF locus of CDKN2A (p ¼ 0.011). Several correlations were found between the four common PDA drivers (TP53, SMAD4, CDKN2A, PTEN) and certain pathological and molecular features. For example, all tumors with PTEN protein loss had CDKN2A mutations/loss (p ¼ 0.0027), and high protein expression of PD-1 was more frequently observed in patients with loss of CDKN2B (p ¼ 0.048), as seen in Table 2 (for diagnosis, complete NGS sequencing, and proteomic results for each patient see Table 3 ).
Patient outcomes and therapy selection
Of the 65 patients with PDA, 52 patients underwent surgical resection and outcomes data were collected on patients who continued receiving care at TJU. Median overall follow-up time was 459 days from time of initial diagnosis. Of the surgically resected patients with available outcomes, 14/42 (33.3%) had no evidence of disease or had recently developed disease recurrence as of last follow-up ( Fig. 2) . Eleven of these patients were on standard of care adjuvant chemotherapy, with initial therapies listed in Fig. 2 . One of these followed a molecularly matched therapy recommendation: a patient with a BRCA2 mutation enrolled in a trial of a PARP inhibitor in combination with FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin).
Survival analysis
Of the 52 patients with resected PDA, we screened the 39 molecular and clinicopathologic features (see Methods for details) against survival data to evaluate correlations with recurrence-free and overall survival. Median follow-up time was 459 days from initial diagnosis. Further analysis of the data showed that almost half of the patients (23/52) had developed disease recurrence, with a Kaplan-Meier estimate of median RFS of 12.4 months. In the patients who did develop disease recurrence,
Fig. 1. Driver and actionable mutations:
Summary of all mutations identified using NGS in the 65 patients with PDA. From those 65 patients, actionable mutations with specific therapeutic options are identified in blue, with common PDA driver genes identified in yellow. most recurrences were in the liver (17 patients), lung (1 patient), brain (1 patient), bone (1 patient), omentum (1 patient), lymph node (1 patient), and one patient had a locally recurrent tumor. Molecular profiling was not repeated after recurrence had occurred in these patients. Fewer than half of the patients (20/52) were deceased, with a Kaplan-Meier estimate of median OS of 21.7 months.
Five variables were correlated with RFS. High expression of three proteins, ERCC1 (p ¼ 0.001), TS (p ¼ 0.005), and PD-1 (p ¼ 0.04), were associated with lower RFS (Fig. 3) . Interestingly, TP53 mutations were correlated with longer RFS (p ¼ 0.01). High tumor grade was negatively correlated with RFS (p ¼ 0.04). No molecular variables were correlated with OS, but two pathologic features were associated with shorter OS: tumor size over 3 cm (p ¼ 0.002) and high histologic grade (p ¼ 0.02).
Discussion
There is a pressing need in today's health care setting for a facile system wherein patient consenting is seamlessly tied to molecular analytic workflow and tracked throughout the course of a patient's treatment. Integrated, structured data are critical for applying statistical and artificial intelligence-based or heuristic algorithms that will be necessary to detect complex relationships between patient data, treatment data, molecular data and treatment response. In this study, we sought to take a first-step to address these data infrastructure-related challenges and demonstrate that a comprehensive precision medicine program can Recent studies have demonstrated that precision medicine can suggest alternative therapeutic strategies in roughly 50% of pancreatic cancer patients [6, 35, 36] . Of the 52 surgically resected PDA patients in this study, 48% harbored at least one actionable alteration, similar to some other studies published [6, 30, 36] . While DNA repair genes and PI3K/mTOR pathway genes had actionable mutations in a relatively high number of patients, no single therapeutic target dominated the actionable alterations (Fig. 1 ). This suggests that profiling of a broad panel of genes is important in PDA in order to identify all potential targets. We note that the frequencies of actionable alterations, in addition to the four common PDA driver alterations, did not differ greatly from published datasets [28, [37] [38] [39] or from the Know Your Tumor dataset of over 600 patients [6] .
One major limitation of this study, and indeed of all similar profiling studies that have been published [30] , is that a limited number of patients that had actionable molecular alterations have gone on to receive matched targeted therapies, especially in a clinical trial. Therefore, it is impossible to draw conclusions about the overall clinical effectiveness of this approach. Moreover, overall follow-up, to date, is not yet long enough to draw any meaningful conclusions about overall impact of the platform on patient care (to this point, in this study 76% of the surgically resected patients have not yet received treatment for recurrent or metastatic disease).
Although we could not perform a statistical analysis correlating molecular and clinicopathologic features with treatment data, we were TMB was either low or not reported unless otherwise specified; Microsatellite instability was not detected in any of these cases.
Fig. 2. Outcomes collection:
Summary of overall outcome data available from patients with PDA enrolled in the study. Outcome data for patients who had long term follow-up in TJU system is represented as of 2018 when the charts were last reviewed with details on any treatment ongoing. NED: no evidence of disease, 5-FU: 5-fluorouracil.
Fig. 3. Recurrence-free survival (RFS) is correlated with molecular and pathologic features:
From the patients with PDA who had long term follow-up at TJU, Kaplan Meier graphs were generated to assess RFS. High expression of ERCC1 (A), TS (B), and PD-1 (C) were correlated with lower RFS. Additionally, mutations in TP53 were correlated with higher RFS(D), while high grade tumors had lower RFS (E). All graphs shown are statistically significant with p values indicated on the graphs. able to find correlations with the time interval of recurrence-free survival (RFS). The high number of significant correlations with RFS ( Fig. 3 ) in this relatively small dataset suggests that as the number of patients analyzed using this platform grows, treatment-specific correlations should become readily detectable. Of the five biomarkers that were significantly correlated with RFS, three were protein-based: ERCC1, TS and PD-1. These markers are putative predictive markers for chemotherapeutic (5-FU) efficacy [40] , platinum based therapy resistance [41] , and potentially future immunotherapeutic strategies. This work supports the notion that proteomic-based testing may also provide additional information for survival and response rates. Interestingly, in our current patient subset we also found that there was an increase in RFS in patients with TP53 mutations compared to TP53 wildtype, which contradicts what was previously published [42] . There have been some inconsistencies in the literature over TP53 mutations and prognostic significance, with some articles considering it a negative prognostic indicator [43] and some articles showing no significance [44, 45] .
Our study establishes that profiling surgically resected primary pancreatic tumors yields a comparable amount of actionable alterations to profiling studies of metastatic sites. This is consistent with studies that showed actionable NGS alteration frequencies did not differ between primary and metastatic PDA [46, 47] . Performing molecular profiling on surgical tissue specimens has multiple important benefits for the timeline of patient care. First, it allows for enough time to plan for therapy if recurrence occurs. This may facilitate enrollment in molecularly targeted clinical trials in the first line of therapy setting, when there is a greater chance of deriving benefit. For example, one patient in a separate study that had a rare IDH1 mutation received an IDH1 inhibitor as third line therapy after developing resistance to FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, oxaliplatin) and gemcitabine with nab-paclitaxel [48] . This patient did not respond to the IDH1 inhibitor, but it is possible that earlier molecular profiling of her tumor could have led to earlier initiation of targeted therapy and a better response [48, 49] . Second, profiling surgical specimens allows time to study the tumor's biology and propagate ex vivo models for various drug sensitivity assays (e.g., organoid model) [29, 50] . Third, profiling a tumor after the administration of neoadjuvant therapy, would allow for a more accurate assessment of the tumor after it has been exposed to potent DNA damaging agents. Finally, this work lays the groundwork for the potential of a personalized adjuvant therapy for patients with lymph node positivity and R1/R2 resections. Based on these theories highlighting the utility of molecular profiling in an oncological setting, there are a couple of potential points of therapeutic intervention (Fig. 4) . With the use of NGS and molecular profiling we can use this additional information to guide oncological therapy in the neoadjuvant and adjuvant settings to allow for the administration of a more unique and personalized therapy for the patient.
In the future, molecular profiling combined with focused drug screens in ex vivo cultures, may inform a personalized approach to treating pancreatic and other cancers. Future randomized controlled trials, along with the optimization of targeted approaches, will determine whether and when molecular profiling will have a role in the treatment of patients with resectable disease (Fig. 4 ). This type of precision medicine platform may allow large hospital systems, such as ours, and cooperative groups to facilitate next generation molecular tumor boards in an effort to scale precision medicine for the benefit of large numbers of patients.
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